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case report
A novel DAX1/NR0B1 mutation 
in a patient with adrenal 
hypoplasia congenita and 
hypogonadotropic hypogonadism
Uma nova mutação DAX1/NR0B1 em um paciente com hipoplasia 
adrenal congênita e hipogonadismo hipogonadotrófico
Claudilene Battistin1, Hamilton Cabral de Menezes Filho1, Sorahia Domenice2, 
Mirian Yumie Nishi2,Thais Della Manna1, Hilton Kuperman1, Leandra 
Steinmetz1, Vaê Dichtchekenian1, Nuvarte Setian1, Durval Damiani1
SUMMARY
We report a case of adrenal hypoplasia congenita (AHC) and hypogonadotropic hypogonadism 
(HH) due to a novel DAX1 mutation. A 19-month-old boy with hyperpigmentation and failure 
to thrive came to our service for investigation. Three brothers of the patient had died due to 
adrenal failure, and a maternal cousin had adrenal insufficiency. Adrenoleukodystrophy was 
excluded. MRI showed normal pituitary and hypothalamus. Plasma hormone evaluation re-
vealed high ACTH (up to 2,790 pg/mL), and low levels of androstenedione, DHEA-S, 11-deoxy-
cortisol, and cortisol. At 14 years of age the patient was still prepubescent, his weight was 43.6 
kg (SDS: -0.87) and his height was 161 cm (SDS: -0.36), with normal body proportions. In the 
GnRH test, basal and maximum values of LH and FSH were respectively 0.6/2.1 and < 1.0/< 1.0 
U/L. Molecular investigation identified a novel mutation that consists of a deletion of codon 
372 (AAC; asparagine) in exon 1 of DAX1. This mutation was not found in a study of 200 al-
leles from normal individuals. Prediction site analysis indicated that this alteration, located 
in the DAX1 ligand-binding domain, may damage DAX1 protein. We hypothesize that the 
novel (p.Asp372del) DAX1 mutation might be able to cause a disruption of DAX1 function, and 
is probably involved in the development of AHC and HH in this patient. Arq Bras Endocrinol Metab. 
2012;56(8):496-500
SUMÁRIO
Relatamos um caso de hipoplasia adrenal congênita (HAC) e hipogonadismo hipogonadotrófico 
(HH) causado por uma nova mutação do gene DAX1. Paciente do sexo masculino com 19 meses 
de idade, hiperpigmentação e desenvolvimento inadequado foi encaminhado ao nosso serviço. 
Antecedente familiar de três irmãos falecidos por falência da adrenal, e um primo materno por-
tador de insuficiência adrenal. Excluída a hipótese de adrenoleucodistrofia. A RM demonstrou 
hipófise e hipotálamo normais. Os níveis de hormônios plasmáticos mostraram alta concen-
tração de ACTH (até 2.790 pg/mL) e baixos níveis de androstenediona, DHEA-S, 11-deoxicortisol 
e cortisol. Aos 14 anos de idade, o paciente ainda era pré-púbere, com peso de 43,6 kg (SDS: 
-0,87) e altura de 161 cm (SDS: -0,36), proporcionado. O teste do GnRH mostrou níveis basais e 
máximos de LH e FSH, respectiva mente, iguais a 0,6/2,1 e < 1,0/< 1,0 U/L. A análise molecular 
identificou uma nova mutação que consiste da deleção do códon 372 (AAC; asparagina) no 
éxon 1 do gene DAX1. Essa mutação não foi encontrada em 200 alelos de indivíduos normais. 
A análise no site PredictProtein indicou que essa alteração, localizada no domínio de ligação do 
DAX1, pode danificar a proteína. Nossa hipótese é que essa nova mutação (p.Asp372del) do 
gene DAX1 pode levar a uma alteração na função da proteína DAX1 e está provavelmente en-
volvida no desenvolvimento da HAC e HH nesse paciente. Arq Bras Endocrinol Metab. 2012;56(8):496-500 
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INTRODUCTION
A drenal hypoplasia congenita (AHC) is a devel-opmental disorder of the adrenal gland, and was 
first described in 1948 by Sikl. It is estimated to affect 
1/12,500 live newborns (1-3). Four clinical forms of 
AHC have been described: 1) a sporadic form, associated 
with hypoplasia of the pituitary gland and characterized 
by small adrenal glands and a reduction of the fetal zone; 
2) a recessive autosomal form, with miniature adult ad-
renal morphology; 3) an X-linked cytomegalic form as-
sociated with hypogonadotropic hypogonadism (HH); 
4) an X-linked form associated with glycerol kinase defi-
ciency and/or Duchenne muscular dystrophy (3,4).
The X-linked cytomegalic form of AHC is charac-
terized by hypofunctioning adrenals, absence of perma-
nent adrenal cortex, and disorganization of the struc-
ture of the gland. These alterations cause early primary 
adrenal insufficiency, characterized by low serum levels 
of glucocorticoids, mineralocorticoids, and androgens, 
and failure to respond to stimulation with adrenocor-
ticotropic hormone (ACTH). Later on, these patients 
are also diagnosed with HH (1,5,6).
The X-linked cytomegalic form of AHC is caused by in-
activating mutations in DAX1/NR0B1 (dosage-sensitive 
sex reversal-adrenal hypoplasia congenita critical region on 
the X chromosome, gene 1/nuclear receptor subfamily 0, 
group B, member 1). This gene encodes an orphan nuclear 
factor that, unlike other members of the nuclear receptor 
superfamily, does not possess a zinc-finger domain (4-
7). DAX1 is located on the short arm of X chromosome 
(Xp21), and is composed by two exons containing, respec-
tively, 1,168 and 254 bp, separated by a 3,385-bp intron. 
It encodes a 470-amino-acid protein (4,6,8).
DAX1 plays a key role in the development of the 
adrenal gland, testis, ovary, pituitary gland, and hypo-
thalamus (3). DAX1 expression colocalizes with that of 
SF1 (steroidogenic factor 1), however not in all tissues. 
DAX1-positive, SF1-negative cells are found in embry-
onic mouse testis, postnatal ovary, and most notably, in 
developing pituitary and hypothalamus, which suggests 
a function for DAX1 that is independent of SF1. How-
ever, how disruption of DAX1 leads to adrenal, hypo-
thalamic, and pituitary developmental defects similar to 
SF1 disruption, still remains to be clarified (9).
Classically, DAX1 mutations have been identified 
in males with primary adrenal insufficiency and HH. 
However, a wide range of phenotypes have been de-
scribed in the literature (10).
This article describes a case of AHC associated with 
HH due to a novel DAX1 mutation.
CASE REPORT
The male patient was first evaluated when he was 19 
months old. He was born from non-consanguineous 
and healthy parents by vaginal delivery, after an un-
eventful pregnancy. His birth weight and birth length 
were respectively 3,080 g (SDS: 0) and 50 cm (SDS: 
-0.79). Maternal menarche was at 11 years old, and 
she had nine pregnancies and three miscarriages. Three 
brothers ha died (at 26, 23 and 11 months) from dehy-
dration and probable adrenal insufficiency, two sisters 
had died from prematurity, and a maternal cousin had 
adrenal insufficiency. The patient was admitted to the 
Pediatric Endocrinology outpatient clinic due to fail-
ure to thrive, darkening of the skin, and excessive thirst 
during the previous 5 months. At physical exam he was 
pale, his weight was 9.7 kg (SDS: -1.92) and his height 
was 80.5 cm (SDS: -0.74). Laboratory tests were com-
patible with a diagnosis of primary adrenal insufficien-
cy: ACTH up to 2,790 pg/mL (normal range: up to 
46 pg/mL), cortisol = 0.2 mg/dL (normal range: 5.4 
to 25 mg/dL). Plasma concentrations of other adre-
nocortical hormones were notably low: androstenedi-
one = 0.3 ng/mL (normal range: 0.3 to 3.3 ng/mL), 
dehydroepiandrosterone sulfate < 20 ng/mL (normal 
range: up to 194 ng/mL), 11-deoxycortisol < 0.4 ng/
mL (normal range: 2.5 to 4.0 ng/mL). Laboratory 
evaluation ruled out adrenoleukodystrophy (normal 
plasma concentration of very long-chain fatty acids) 
and glycerol kinase deficiency. Radiological evaluation 
(adrenal ultrasonography and brain MRI) was normal.
The patient was treated with glucocorticoid and 9a-
fluodrocortisone, with dosages adjusted during follow-
up. However, adherence to treatment was not satisfac-
tory, so the patient experienced several episodes of acute 
adrenal insufficiency followed by seizures. At these mo-
ments, electrolyte plasma concentrations confirmed 
mineralocorticoid insufficiency: sodium = 123 mEq/L 
(normal range: 135 to 147 mEq/L), and potassium = 
6.0 mEq/L (normal range: 3.6 to 4.8 mEq/L). These 
episodes were treated with intravenous hydrocortisone 
and blood volume replacement. Table 1 shows the hor-
monal and electrolytic profile of the patient.
During his follow-up, cryptorchidism was found on 
the right side. The testicle was palpable in the inguinal 
canal. A human chorionic gonadotropin (hCG) stimu-
lation test (single dose of 3,000 U/m2) suggested com-
promised testicular function (testosterone after hCG = 
14 ng/dL). The patient was subjected to orchidopexy 
at the age of 10.
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Clinical evaluation at 14 years old identified absent 
pubertal signs (Tanner stage P1G1, testicular volume 
= 2 mL, bilaterally). At this time, the patient reached 
weight of 43.6 kg (SDS: -0.87) height of 161 cm (SDS: 
Molecular analysis and results
Genomic DNA was isolated from peripheral blood leu-
kocytes of the patient. Both exons of DAX1/NR0B1A 
(ENSG00000169297) and the intronic flanking sequen-
ces were amplified by polymerase chain reaction using spe-
cific primers and conditions, as described elsewhere (11). 
The amplicons were submitted to enzymatic purification 
with ExoSAP-IT kit (GE Healthcare Life Sciences, CT, 
USA), and directly sequenced using BigDye™ Terminator 
Cycle Sequencing Ready Reaction Kit (Life Technologies, 
CA, USA) in an ABI PRISM 3100 automatic sequencer. 
Samples from 100 controls were also analyzed.
An allelic variant of DAX1/NR0B1A was identified 
and its functional effects were predicted, in silico, using 
PolyPhen, SIFT, and PredictProtein software (12-14). 
The sequencing of DAX1/NR0B1A identified the 
allelic variant c.1114_1116delAAC (p.Asp372del) in 
exon 1 (Figure 2). This variant was not identified in a 
study of 200 alleles from normal individuals. Adapted 
analysis of this DAX1 variant protein using PolyPhen 
and SIFT programs indicated that this alteration may 
damage the protein. 
PredictProtein analysis suggested that the dele-
tion of the amino acid (Asp) changed the second-
ary structure of the protein by eliminating a loop in 
this region (14). In the wild-type DAX1 protein, this 
Table 1. Hormonal and electrolytic profile during follow-up
Age (months) ACTH (pg/mL) DHEA (ng/mL) Na/K (mEq/L)
30 _ 0.5 123/6.0
70 328 _ 142/4.4
147 _ _ 128/5.5
157 2,790 < 0.1 140/4.2
165 1,160 _ 140/4.6
ACTH: adrenocorticotropic hormone; DHEA: dehydroepiandrosterone; 
Na: sodium; K: potassium.
-0.36), and exhibited hyperpigmentation of the oral 
cavity (Figure 1). Response to stimulation with gonad-
otropin-releasing hormone (GnRH) was decreased, 
and bone age was delayed (12.5 years, SDS:-1.54).
A sample of the patient’s peripheral blood was col-
lected for molecular analysis after informed consent was 
provided.
Figure 1. Clinical features of the patient at 14 years of age. Note the 
hyperpigmentation of the oral mucosa (A) and the pre-pubescent 
appearance (B).
Figure 2. Electropherograms of the reverse sequence of DAX1/NR0B1A 
exon 1 in (A) a control and (B) the index case. Deletion of three nucleotides 
(AAC) at position 1114-1116 leads to the loss of the amino acid asparagine 
at position 372. 
A
A
B
B
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loop consists of three amino acids (asparagine, isoleu-
cine, serine) beginning at Asp372. In the absence of 
asparagine, the loop disappears.
DISCUSSION
Inactivating DAX1 mutations are well-established etio-
logies of the association between X-linked AHC and HH 
(OMIM:300200) (15). Deletions and point mutations 
within the DAX1 gene have been described in more 
than 70 families exhibiting AHC (7,16). The prevalence 
of inactivating DAX1 mutations in the male population 
is estimated at 1:70,000 to 1:600,000 (17,18).
DAX1 is expressed in the adrenal gland, gonads, hy-
pothalamus, and pituitary gonadotropes (3,8,15,17), 
and plays a significant role at several levels of the func-
tion and development of the reproductive axis (15). 
HH in patients with DAX1 mutations involves defi-
ciencies at both hypothalamic and pituitary levels. Ser-
toli cells also express the DAX1 gene, and DAX1-/- 
rats exhibit reduced spermatogenesis and fertility (6). 
In most male patients with DAX1 inactivation, 
AHC is manifested in infancy and childhood by means 
of episodes of salt loss characterized by vomiting, diar-
r hea, dehydration, hyponatremia, hyperkalemia, and 
hypoglycemia. These episodes are frequently triggered 
or aggravated by acute stress (usually an acute viral in-
fection), and may be accompanied by seizures. Later, 
these patients are further characterized by delayed pu-
berty due to HH (10,17,19).
In 2006, Lin and cols. described a case series includ-
ing 64 male patients with primary adrenal insufficiency. 
The symptoms occurred before the first year of life in 
79% of these patients, while DAX1 mutations were 
identified in 59% of patients (18). In 2010, Landau and 
cols. described 12 patients with DAX1 mutations in Is-
raeli families and reported that clinical manifestations 
were noted before the age of 8 weeks in 83% of these 
patients (17). In Li’s case series, however, signs and 
symptoms were noticed later, usually after the age of 2 
years (19). In the patient described in this article, clini-
cal manifestations were noticed at the age of 14 months.
The vast majority of boys with DAX1 mutations 
described in the literature evolve with delayed puberty, 
characterized by absence of secondary sexual character-
istics beyond age 14 (3,15,16,19,20,21). In some pa-
tients, incomplete pubertal development and a marked 
reduction of testicular volume have also been noted 
(19,22,23). Li and cols. showed that the expression 
of GnRH is increased in a dose-dependent manner by 
steroidogenic factor 1 (SF1) in individuals with normal 
DAX1; in those with DAX1 mutations (e.g., p.R267P, 
p.L262P, p.C368F, c.637delC, c.652_653delAC), 
there is a severe decrease in GnRH expression, explain-
ing the presence of HH (19).
The patient described in this article exhibited a pro-
file compatible with delayed puberty, failing to respond 
to stimulation with GnRH at the age of 14, which sup-
ports the hypothesis of HH. However, he had been 
previously subjected to right-side orchidopexy with un-
satisfactory testosterone response to hCG stimulation, 
suggesting compromised testicular function, probably 
due to a lack of gonadotropic stimulation. Chronically 
non-stimulated testes require longer-term stimulation 
with higher doses of hCG in order to produce prop-
er serum levels of testosterone. In the case described 
here, we performed the test with a single dose of hCG 
because several previous attempts to conduct 4-week 
stimulation tests failed due to patient non-compliance.
Curiously, in 2001, Domenice and cols. described a 
male patient with a DAX1 mutation and early puberty 
with enlarged testes, but with prepubertal levels of lu-
teinizing hormone. Treatment with a GnRH analogue 
did not reduce plasma levels of testosterone, which 
were only achieved after treatment with glucocorticoid 
and mineralocorticoid. Thus, this patient represents a 
case of ACTH-dependent early puberty in which the 
synthesis and secretion of testosterone by Leydig cells 
was stimulated by means of the activation of melano-
cortin receptor 1 (10). Ahmad and cols. described a 
similar case of a patient with AHC and bilateral increase 
of testicular volume, but the disorder seemed to be in-
dependent of ACTH, and treatment with glucocorti-
coid did not reduce testicular size (24). 
Seminara and cols. described several families in 
which women heterozygous for DAX1 mutations ex-
hibited delayed puberty. In all cases, the most notice-
able clinical manifestation was delayed menarche (aver-
age of 17 years) without associated adrenal involvement 
or infertility (6,15). Although the molecular studies of 
the mother were lost, her puberty was apparently nor-
mal since her menarche occurred at 11 years of age.
It is evident that many contributions to the molecu-
lar investigation of adrenal disorders in childhood have 
been made over the last 15 years (18). Up to mid-2006, 
approximately 80 to 100 DAX1 mutations had been 
described (8,20). Currently, approximately 200 DAX1 
mutations are known, including deletions involving the 
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NR0B1 gene alone or along adjacent genes, such as the 
gene associated with Duchenne muscular dystrophy or 
glycerol kinase, in a kind of “contiguous gene syndrome” 
and nonsense, frameshift, or missense mutations (22). 
Most mutations are frameshift or nonsense substitutions 
that give rise to truncated proteins with significant loss-
of-function effects (25). A complete phenotype-geno-
type correlation has not been established yet.
In the case described here, a novel allelic variant 
of DAX1 was characterized by a deletion of three 
base pairs (AAC) from exon 1, resulting in the loss of 
one asparagine (codon 372). PredictProtein analysis 
showed that the wild-type DAX1 protein contained 
a three-amino-acid loop at positions 372-374 (aspara-
gine, isoleucine, serine). In the absence of Asp372, 
this loop disappears, causing a significant change 
in the secondary structure of the DAX1 protein. 
We hypothesize that this change would disrupt the 
function of the DAX1 protein because the missing 
amino acid is located in the ligand-binding domain, 
an important region of the protein. 
In conclusion, the possibility of an inactivating 
DAX1 mutation must be considered in all male pa-
tients with a clinical profile compatible with early-onset 
primary adrenal insufficiency.
The identification of DAX1 mutations is important 
for genetic counseling regarding future pregnancies, 
and especially for the early identification of patients at 
risk for episodes of acute primary adrenal insufficiency, 
which are associated to high morbidity and mortality.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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